September 8, 2026
Moonwalk Biosciences
Moonwalk Biosciences is developing adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases.
- Round
- Series B
- Amount raised
- $70M
- Lead investor
- —
- Industry
- Biotechnology
- Headquarters
- CA
- Employees
- 11-50 employees
- Website
- moonwalk.bio
- View profile →